Skip to main content
Caplight Logo









Neurosterix

Neurosterix

Private
GenevaHealthcare & Life Scienceshttps://neurosterix.com/

Last Round

Series A

Apr 3, 2024

Est. Valuation

$98M

Total Funding Raised

$65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neurosterix is a biopharmaceutical company that develops allosteric modulator therapeutics for the treatment of neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

allosteric modulatorM4 PAMschizophrenia drugclinical-stage biotechdrug discoveryneurological disordersbiotech spin-outCNS therapeuticspositive allosteric modulatorsmall-molecule drugneuroscience startupclinical pipelinepharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurosterix Comparables

Compare Neurosterix with similar companies based on industry and business-model similarity.

Neurosterix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Addex Therapeutics
81%
Neumora
80%
Noema Pharma
75%

Neurosterix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 3, 2024

Neurosterix Investors

Notable investors and investment history

Neurosterix investors
InvestorRounds
Perceptive AdvisorsSeries A
XontogenySeries A
Acorn BioventuresSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 43% MoM, reaching 1K.

  • Jul 25, 2026

    Monthly visitors increased 702% MoM.

Recent news

Latest coverage and updates

  • is_developingSep 27, 2026

    Neurosterix is developing NTX-253 on Sep 28th '26.

Neurosterix Filings

Explore SEC and related filing metadata, where available.

Neurosterix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neurosterix's valuation, stock price, and market status.

Is Neurosterix a public or private company?

Neurosterix is a private company.

What is the current stock price of Neurosterix?

Neurosterix is a private company with no public stock price. No recent secondary market data is available.

How much is Neurosterix worth (valuation)?

Neurosterix's valuation is estimated at $98.0M based on funding round data.

Can I buy Neurosterix stock?

Neurosterix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neurosterix's last funding round?

Neurosterix's most recent funding round was Series A on April 2, 2024.

Who are the main investors in Neurosterix?

Key investors in Neurosterix include Perceptive Advisors, Xontogeny.

Will Neurosterix IPO soon?

No public IPO plans have been announced for Neurosterix.

How can I track Neurosterix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurosterix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGeneva
Employee Range21
Year Founded2024
Last FundingApr 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?